Verrica's YCANTH Drives Revenue Growth, Narrows Q2 Loss

TL;DR

**Verrica's YCANTH is finally generating revenue, but the path to profitability is still a long, expensive climb.**

AI Summary

Verrica Pharmaceuticals Inc. reported product revenue of $1.5 million for the three months ended June 30, 2025, and $2.8 million for the six months ended June 30, 2025, primarily from its YCANTH product. This represents a significant increase from zero product revenue in the comparable periods of 2024, following YCANTH's commercial launch in September 2023. The company's net loss for the three months ended June 30, 2025, was $14.2 million, a decrease from a net loss of $18.5 million in the prior year period. Research and development expenses decreased to $2.9 million for the three months ended June 30, 2025, from $5.3 million in the same period of 2024, reflecting the shift from clinical development to commercialization. Selling, general, and administrative expenses increased to $12.3 million for the three months ended June 30, 2025, from $10.9 million in 2024, driven by commercialization efforts for YCANTH. A key strategic development is the First Amendment to the Torii Agreement on May 14, 2024, which could lead to up to $70.0 million in regulatory milestone payments from Torii Pharmaceutical Company Limited. The company faces risks related to its ability to achieve profitability and generate sufficient cash flows from YCANTH sales, as evidenced by its accumulated deficit of $448.8 million as of June 30, 2025. The strategic outlook focuses on maximizing YCANTH's market penetration and managing operating expenses.

Why It Matters

Verrica's ability to generate $1.5 million in product revenue from YCANTH in Q2 2025, a significant jump from zero in the prior year, is crucial for investors as it demonstrates initial market traction for its sole commercial product. This revenue growth, coupled with a reduced net loss of $14.2 million, suggests a potential path towards profitability, impacting investor confidence and future capital raises. For employees, the focus on YCANTH's commercialization provides job stability and growth opportunities within the sales and marketing teams. Customers, specifically patients with molluscum contagiosum, benefit from increased access to YCANTH, potentially improving treatment outcomes. In the competitive landscape, Verrica's success with YCANTH could position it as a key player in the dermatology market, challenging existing treatments and attracting further partnerships like the one with Torii Pharmaceutical Company Limited.

Risk Assessment

Risk Level: medium — The risk level is medium due to Verrica's continued net losses, with an accumulated deficit of $448.8 million as of June 30, 2025, indicating a history of unprofitability. While product revenue from YCANTH reached $1.5 million in Q2 2025, the company's ability to sustain and significantly grow this revenue to cover increasing selling, general, and administrative expenses of $12.3 million remains a substantial challenge.

Analyst Insight

Investors should monitor YCANTH's sales trajectory closely in upcoming quarters to assess if revenue growth can outpace operating expenses. Consider holding if current YCANTH sales trends continue to improve, but be prepared for potential dilution if the company needs to raise additional capital to fund its operations given its accumulated deficit.

Financial Highlights

debt To Equity

N/A

revenue

$1.5M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$14.2M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $1.5M — Product Revenue (Generated in Q2 2025, up from $0 in Q2 2024, indicating initial YCANTH market penetration.)
• $14.2M — Net Loss (Reduced from $18.5M in Q2 2024, showing improved financial performance.)
• $2.9M — R&D Expenses (Decreased from $5.3M in Q2 2024, reflecting a shift to commercialization.)
• $12.3M — SG&A Expenses (Increased from $10.9M in Q2 2024, driven by YCANTH commercialization efforts.)
• $448.8M — Accumulated Deficit (As of June 30, 2025, highlighting historical unprofitability and ongoing financial challenges.)
• $70.0M — Potential Milestone Payments (From Torii Pharmaceutical Company Limited, offering future revenue potential.)

Key Players & Entities

• Verrica Pharmaceuticals Inc. (company) — filer of the 10-Q
• YCANTH (product) — Verrica's primary commercial product
• Torii Pharmaceutical Company Limited (company) — partner in a licensing agreement
• $1.5 million (dollar_amount) — product revenue for Q2 2025
• $2.8 million (dollar_amount) — product revenue for the six months ended June 30, 2025
• $14.2 million (dollar_amount) — net loss for Q2 2025
• $18.5 million (dollar_amount) — net loss for Q2 2024
• $2.9 million (dollar_amount) — R&D expenses for Q2 2025
• $5.3 million (dollar_amount) — R&D expenses for Q2 2024
• $448.8 million (dollar_amount) — accumulated deficit as of June 30, 2025

FAQ

Risk Factors

• Achieving Profitability and Cash Flow [high — financial]: The company has an accumulated deficit of $448.8 million as of June 30, 2025. Generating sufficient cash flows from YCANTH sales is critical to achieving profitability and sustaining operations.
• YCANTH Market Penetration [medium — market]: While YCANTH generated $1.5 million in Q2 2025 revenue, its market penetration is still in its early stages post-launch in September 2023. Success hinges on continued market adoption and sales growth.
• Dependence on Milestone Payments [medium — financial]: The potential for up to $70.0 million in regulatory milestone payments from Torii Pharmaceutical Company Limited, as per the First Amendment to the Torii Agreement on May 14, 2024, represents a significant, albeit contingent, future revenue stream.
• Commercialization Expense Management [medium — operational]: Selling, general, and administrative expenses increased to $12.3 million in Q2 2025, driven by YCANTH commercialization efforts. Managing these costs effectively is crucial for improving the bottom line.

Industry Context

The pharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies like Verrica focus on niche therapeutic areas, aiming for market penetration with innovative treatments. The competitive landscape involves established players and emerging biotechs, with success often depending on effective commercialization strategies and strategic partnerships.

Regulatory Implications

Verrica's operations are subject to stringent FDA regulations for drug approval and post-market surveillance. The success of YCANTH relies on continued compliance and adherence to these regulations. Any adverse regulatory actions could significantly impact product sales and future development.

What Investors Should Do

1. Monitor YCANTH sales trajectory and market share gains.
2. Track progress and potential realization of Torii milestone payments.
3. Analyze SG&A expense trends relative to revenue growth.

Key Dates

• 2023-09-01: YCANTH Commercial Launch — Marks the beginning of product revenue generation for Verrica Pharmaceuticals.
• 2024-05-14: First Amendment to the Torii Agreement — Introduced the potential for up to $70.0 million in regulatory milestone payments, providing a significant future revenue opportunity.
• 2025-06-30: End of Q2 2025 — Reporting period for the 10-Q, showing $1.5M in product revenue and a net loss of $14.2M.

Glossary

YCANTH

Verrica Pharmaceuticals' lead product, a treatment for common and juvenile plantar warts. (The primary driver of current and future product revenue for the company.)

Accumulated Deficit

The total cumulative net losses of a company since its inception, representing the excess of expenses over revenues. (Indicates Verrica's historical unprofitability and the significant financial challenge of reaching breakeven.)

Torii Agreement

An agreement with Torii Pharmaceutical Company Limited, which includes provisions for milestone payments related to regulatory approvals. (Represents a key potential source of future non-dilutive funding for Verrica.)

SG&A Expenses

Selling, General, and Administrative expenses, which include costs associated with marketing, sales, and general business operations. (These expenses have increased due to YCANTH's commercialization, impacting the company's net loss.)

Year-Over-Year Comparison

Compared to the prior year period, Verrica Pharmaceuticals has transitioned from zero product revenue to $1.5 million in Q2 2025, driven by the YCANTH launch. This revenue growth is accompanied by a reduced net loss ($14.2M vs. $18.5M), reflecting improved operational efficiency. However, R&D expenses have decreased significantly ($2.9M vs. $5.3M) as the company shifts focus to commercialization, leading to an increase in SG&A expenses ($12.3M vs. $10.9M).

Key Financial Figures

• $0.0001 — nge on which Registered Common Stock, $0.0001 par value VRCA The Nasdaq Stock Mar

Filing Documents

• vrca-20250630.htm (10-Q) — 2280KB
• vrca-ex10_1.htm (EX-10.1) — 82KB
• vrca-ex10_2.htm (EX-10.2) — 112KB
• vrca-ex31_1.htm (EX-31.1) — 15KB
• vrca-ex31_2.htm (EX-31.2) — 15KB
• vrca-ex32_1.htm (EX-32.1) — 13KB
• 0000950170-25-107358.txt ( ) — 10462KB
• vrca-20250630.xsd (EX-101.SCH) — 1265KB
• vrca-20250630_htm.xml (XML) — 2189KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risks

Quantitative and Qualitative Disclosures About Market Risks 30 Item 4.

Controls and Procedures

Controls and Procedures 30

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 31 Item 5. Other Information 31 Item 6. Exhibits 31

FINANC IAL INFORMATION

PART I. FINANC IAL INFORMATION

Unaudited Financial Statements

Item 1. Unaudited Financial Statements VERRICA PHARMACEUTICALS INC. BA LANCE SHEETS (in thousands, except share and per share amounts) (Unaudited) June 30, December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 15,396 $ 46,329 Accounts receivable 9,193 48 License and collaboration receivable, billed and unbilled 8,178 29 Inventory 2,522 2,463 Prepaid expenses and other current assets 1,492 2,310 Total current assets 36,781 51,179 Property and equipment, net 315 589 Operating lease right-of-use asset 690 836 Finance lease right-of-use asset 945 1,154 Other non-current assets 376 376 Total assets $ 39,107 $ 54,134 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable $ 2,321 $ 1,896 Accrued expenses and other current liabilities 13,101 13,511 Deferred revenue 481 - Current portion of long-term debt 12,673 12,938 Operating lease liability 328 315 Finance lease liability 318 352 Total current liabilities 29,222 29,012 Operating lease liability 416 583 Finance lease liability 579 768 Derivative liability 1,796 2,648 Long term debt 24,578 30,983 Total liabilities 56,591 63,994 Commitments and Contingencies (Note 6) Stockholders' deficit: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of June 30, 2025 and December 31, 2024 — — Common stock, $ 0.0001 par value; 200,000,000 authorized; 9,265,034 shares issued and 9,254,520 shares outstanding as of June 30, 2025 and 9,188,513 shares issued and 9,177,999 shares outstanding as of December 31, 2024 1 1 Treasury stock, at cost, 10,514 shares as of June 30, 2025 and December 31, 2024 — — Additional paid-in capital 299,080 297,166 Accumulated deficit ( 316,565 ) ( 307,027 ) Total stockholders' deficit ( 17,484 ) ( 9,860

Notes to Financial Statements

Notes to Financial Statements (Unaudited) Note 1— Organization and Description of Business Operations Verrica Pharmaceuticals Inc. (the "Company") was formed on July 3, 2013 and is incorporated in the State of Delaware. The Company is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. On July 21, 2023, the U.S. Food and Drug Administration ("FDA") approved YCANTH (VP-102) topical solution for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. Reverse Stock Split At the close of trading on July 24, 2025, the Company effected a reverse stock split at a ratio of 1-for-10 shares of its common stock. As a result, every ten shares of the Company's issued and outstanding common stock were automatically combined into one share. The reverse stock split affected all stockholders uniformly and did not alter any stockholder's percentage ownership interest in the Company. This split reduced the number of issued shares of common stock from 92,650,404 shares to 9,265,034 shares of common stock. The number of shares of the Company's common stock outstanding was reduced from 92,545,260 to 9,254,520 . No fractional shares were issued as a result of the reverse stock split and the split did not impact the par value of the Company's common stock. Any fractional shares that would otherwise have resulted from the reverse stock split were rounded down to the next whole share. While the reverse stock split occurred subsequent to the quarter ended June 30, 2025, the accompanying financial statements and footnotes have been adjusted to reflect the impact of the reverse stock split as though it had occurred in all periods presented. Liquidity and Capital Resources The Company has incurred substantial operating losses since inception and expects to continue to incur significant losses for the foreseeable future and may never become profitable. As of June 30, 20

View Full Filing

View this 10-Q filing on SEC EDGAR